title: Raloxifene trial in postmenopausal woman with treatment-resistant schizophrenia.
abstract: Raloxifene augmentation in postmenopausal women with schizophrenia has shown promising results. Younger patients diagnosed as treatment-resistant schizophrenia and treated with raloxifene (120 mg/day) have reported significant improvement in symptoms. This case highlights how raloxifene, a selective estrogen receptor modulator (SERM), can play a major role in alleviating positive and negative symptoms in postmenopausal women with treatment-resistant schizophrenia.
authors.affiliation: Schizophrenia Research Foundation, R/7A, North Main Road, Chennai, 600101, India, hematharoor@scarfindia.org.
authors.forename: Hema
authors.initials: H
authors.lastname: Tharoor
authors.forename: Aparna
authors.initials: A
authors.lastname: Goyal
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause / Q000187:drug effects*; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride